News
GlyTech, Inc. Signs Agreement on Clinical Development of Glycosylated Somatostatin with YungShin Pharmaceutical Industrial Co.
GlyTech, Inc. has signed an agreement with YungShin Pharmaceutical Industrial Co. to accelerate the clinical development of glycosylated somatostatin (G-SRIF). The Phase 1 clinical trial of G-SRIF is scheduled to begin in early 2020. For more information on the collaborative clinical development agreement with YungShin Pharmaceutical Industrial Co.
Last updated: